Coya Therapeutics, Inc. 8-K

What Happened

• On March 16, 2026, Coya Therapeutics, Inc. (COYA) filed a Form 8-K (Item 2.02) announcing it issued a press release disclosing its results of operations and financial condition for the fiscal year ended December 31, 2025.
• The press release was furnished with the filing as Exhibit 99.1; the Form 8-K was signed by CEO Arun Swaminathan, Ph.D.

Key Details

• Filing date: March 16, 2026 (Form 8-K, Item 2.02).
• Reporting period: fiscal year ended December 31, 2025.
• Disclosure format: press release furnished as Exhibit 99.1 (and the cover page interactive XBRL as Exhibit 104).
• Authorized and signed by CEO Arun Swaminathan, Ph.D.

Why It Matters

• This filing signals COYA has publicly disclosed its full-year 2025 operating and financial results; investors should read the accompanying press release and any related financial statements for revenue, profit/loss, cash position and commentary on operations.
• Key financial metrics and management commentary in the press release can influence short-term stock movement and help assess the company’s cash runway, R&D spend and progress on its clinical or product programs.
• If you own or are considering COYA shares, review the Exhibit 99.1 press release and any subsequent SEC filings for detailed figures and guidance.